BiotechTube

ALN-TTRSC (revusiran) + Sterile Normal Saline (0.9% NaCl)

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

TTR-mediated Amyloidosis

Conditions

TTR-mediated Amyloidosis

Trial Timeline

Mar 1, 2013 → May 1, 2015

NCT ID
NCT01814839

About ALN-TTRSC (revusiran) + Sterile Normal Saline (0.9% NaCl)

ALN-TTRSC (revusiran) + Sterile Normal Saline (0.9% NaCl) is a phase 1 stage product being developed by Alnylam Pharmaceuticals for TTR-mediated Amyloidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01814839. Target conditions include TTR-mediated Amyloidosis.

What happened to similar drugs?

0 of 1 similar drugs in TTR-mediated Amyloidosis were approved

Approved (0) Terminated (0) Active (1)
🔄patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01814839Phase 1Completed

Competing Products

7 competing products in TTR-mediated Amyloidosis

See all competitors
ProductCompanyStageHype Score
ALN-TTR02 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26
ALN-TTRSC (revusiran) for subcutaneous administrationAlnylam PharmaceuticalsPhase 2
32
PatisiranAlnylam PharmaceuticalsPhase 2
32
Revusiran (ALN-TTRSC)Alnylam PharmaceuticalsPhase 2
32
patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3
37
ALN-TTR02 (patisiran) administered by intravenous (IV) infusionAlnylam PharmaceuticalsPhase 2
32
patisiran (ALN-TTR02)Alnylam PharmaceuticalsPre-clinical
23